Rewalk Robotics Ltd
NASDAQ:LFWD
Rewalk Robotics Ltd
ReWalk Robotics Ltd. Is a medical device company, which engages in the design, development and marketing of wearable robotic exoskeletons. The firm is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The firm offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement. ReWalk designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The firm offers two ReWalk products: ReWalk Personal and ReWalk Rehabilitation. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities, and is custom fitted for each user. ReWalk Rehabilitation is designed for use by paraplegia patients in the clinical rehabilitation environment, where it provides exercise and therapy.
ReWalk Robotics Ltd. Is a medical device company, which engages in the design, development and marketing of wearable robotic exoskeletons. The firm is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The firm offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement. ReWalk designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The firm offers two ReWalk products: ReWalk Personal and ReWalk Rehabilitation. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities, and is custom fitted for each user. ReWalk Rehabilitation is designed for use by paraplegia patients in the clinical rehabilitation environment, where it provides exercise and therapy.
Revenue Growth: Q3 revenue increased to $6.2 million, up 8% sequentially and 1.1% year-over-year, driven mainly by higher Medicare unit sales in the U.S.
Record ReWalk Placements: Lifeward delivered a record number of ReWalk exoskeleton units to Medicare beneficiaries for the second consecutive quarter following CMS fee schedule establishment.
Efficiency Gains: Operational improvements led to a 16% reduction in quarterly cash burn and a 27% decline in non-GAAP operating loss over last year.
Margin Expansion: Gross profit margin rose to 43.7% from 36.2% last year due to cost reductions after closing the Fremont, CA facility.
Liquidity Boost: Lifeward secured a $3 million loan after quarter-end, enhancing near-term liquidity.
Guidance Reaffirmed: Full-year 2025 revenue guidance of $24–26 million and non-GAAP net loss of $12–14 million was reaffirmed.
Global Expansion: CE Mark approval has expanded Lifeward’s European opportunity, with Germany showing strong pipeline momentum.
